The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | FEDORA preliminary analysis: fedratinib plus ropeginterferon alfa-2b in patients with myelofibrosis
Adam Mead, MA, BM, BCh, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the preliminary analysis of the FEDORA study (ISRCTN88102629), a Phase II trial evaluating the combination of fedratinib and ropeginterferon alfa-2b in patients with myelofibrosis (MF). Dr Mead notes that results to date are encouraging, with the combination resulting in spleen responses, symptom improvement, and reduction in JAK2 allele burden. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
